IFNL4 Antibody, Biotin conjugated

Code CSB-PA20629D0Rb
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) IFNL4 Polyclonal antibody
Uniprot No. K9M1U5
Target Names IFNL4
Alternative Names IFN-lambda-4 antibody; IFNAN antibody; IFNL4 antibody; IFNL4_HUMAN antibody; Interferon lambda-4 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Interferon lambda-4 protein (34-76AA)
Immunogen Species Homo sapiens (Human)
Conjugate Biotin
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Cytokine that may trigger an antiviral response activating the JAK-STAT pathway and up-regulating specifically some interferon-stimulated genes.
Gene References into Functions
  1. These results demonstrate that virus-induced IFN-lambda4 potently blocks IFN-alpha signalling by inducing high protein levels of ISG15 and USP18. Moreover, the data clearly demonstrate that DAA therapy restores IFN-alpha responsiveness in HCV-infected cells. PMID: 28630501
  2. The results show that IFNL4 ss469415590 DeltaG/DeltaG genotype was associated with poor virological response to anti-hepatitis C combination therapy. PMID: 30480920
  3. Studied the association of interferon-lambda 4 (IFNL4)-related polymorphisms and human leukocyte antigen (HLA)-B haplotypes within long-term nonprogressor HIV-1 controllers (LTNP-Cs); HLA-B*57 was independently associated with the LTNP-C phenotype, while IFNL4 genotypes represented independent factors for becoming non-LTNP-C. PMID: 27986689
  4. IFNL4 genotype might predict DAA-response. PMID: 29866411
  5. our study validated that IFNL4 ss469415590 was also strongly associated with HCV clearance in Chinese Han population. PMID: 28186161
  6. IFN-lambda4 suppressed HIV infection of macrophages. This IFN-lambda4-mediated HIV inhibition was compromised by the antibodies against IFN-lambda receptor complex, IFN-lambdaR1/IL-10R2. PMID: 30247785
  7. Analysis of the IFNL4 polymorphism rs368234815 in association with human papillomavirus (HPV) results, does not suggest its possible role during low or high-risk with HPV infection or in determining HPV outcome (clearance/reinfection or persistence/high-grade lesion). PMID: 29243064
  8. Significant associations were observed for 4 variants in IFNAR2, IFNLR1 with hepatitis B virus infection, and IFNLR1-rs4649203 was associated with hepatitis B recovery. Moreover, the authors demonstrated the clear relevance of 5 polymorphisms in IFNA1, IFNA2, IFNL4 with hepatocellular carcinoma. PMID: 29080269
  9. It has been shown that age, spontaneous lymphocyte proliferation, and an IFNL4 polymorphism were associated with progression to HTLV-I-associated myelopathy-tropical spastic paraparesis. PMID: 29129607
  10. IFNL locus SNPs are subject to either a positive or a negative confounding effect by rs117648444. PMID: 28727946
  11. Intrahepatic expression of IFNL4 was associated with increased antiviral interferon-stimulated gene (ISG) expression and decreased suppressive ISG expression at baseline, resulting in poor responsiveness to IFNalpha-based therapy in HCV infection. PMID: 28036111
  12. The association between IFNL3/4 genotypes with elevated HCV VL observed in HCV g6-infected individuals may have implications for the progression of liver disease in Southeast Asian countries where this viral genotype predominates and therefore warrants further studies. PMID: 29022122
  13. Interferon lambda polymorphisms influence regulatory pathways of cellular response to interferon and affect body iron balance in chronic hepatitis C virus infection. PMID: 27125837
  14. Studied involvement of two interferon lambda 4 (IFNL4) single nucleotide polymorphisms in predicting sustained virologic response (SVR) following antiviral therapy in patients with inherited bleeding disorder and chronic hepatitis C. PMID: 27735085
  15. these results suggest unique functional properties of IFN-lambda4 that can be important in viral clearance and other clinical conditions PMID: 29070670
  16. rs368234815 TT/TT genotype associated with severity of fibrosis in nonalcoholic fatty liver disease patients of European ancestry PMID: 28741298
  17. Data show that the genotype distributions of IFNL3 and IFNL4 variants (rs4803217, rs368234815, rs117648444, and rs12979860) were in Hardy-Weinberg equilibrium. PMID: 28394349
  18. Data show that interferon lambda 4 (IFNL4) genotypes determine hepatitis C virus (HCV) viral load through a mechanism dependent on a specific amino acid residue in the HCV NS5A protein. PMID: 28394351
  19. This study provides mechanistic evidence that humans suppress IFNlambda4 expression, suggesting that immune function is dependent on other IFNL family members. PMID: 27799623
  20. Donor IFNL4 TT/TT genotype, a favorable predictor of spontaneous HCV clearance pre-transplant, is associated with increased early post-transplant fibrosis and decreased survival. PMID: 27875564
  21. the association of amino acid substitutions in the HCV core protein and the IFNL3 and IFNL4 polymorphisms with the severity of liver disease, particularly in hepatocellular carcinoma development PMID: 27035616
  22. Population Polymorphism of IFNL3 and IFNL4 Genes of Type 3 Interferon Associated with Spontaneous Clearance of Hepatitis C Virus in Representatives of Caucasian and Mongoloid Races PMID: 27492404
  23. There was no association between IFNL4 polymorphism and HBV susceptibility or natural clearance. PMID: 27236152
  24. this meta-analysis suggests that IFNL4 genetic polymorphism may be a predictor of sustained virological response in chronic hepatitis C patients PMID: 27180197
  25. In this study, there was association of the three isolated polymorphisms (rs8099917, rs12979860 and rs368234815) with both clinical outcome and response to treatment with PEG-IFN and RBV in chronic hepatitis C. PMID: 26973228
  26. There were no statistically significant differences in endogenous interferon-stimulated genes (ISGs) mRNA levels among HIV-1-positive patients bearing different IFNL4 genotypes, suggesting that ISG expression is independent of the IFNL4 genotype in HIV-1 infection. PMID: 27558125
  27. Single-nucleotide polymorphisms (rs12979860) in the intronic region of the interferon-lambda4 (IFNL4) gene modulate liver inflammation and fibrosis, in an etiology independent manner. PMID: 26592354
  28. IFNL4-DeltaG/TT is the primary IFN-lambda region polymorphism for impaired HCV clearance PMID: 26186989
  29. this report shows that NF-kappa B, IRF3, IRF7, and the GC-rich DNA-binding transcription factor, Sp1, have key roles in stimulating transcription from the IFNL4 promoter. PMID: 26684959
  30. Despite differences in protein sequences, functional properties of the recombinant human and nonhuman IFN-l4 proteins are comparable-they are all biologically active for induction of interferon signaling. PMID: 26308395
  31. suggest that IFN-lambda4 protein expression associated with the IL28B-T/T variant preactivates the Janus kinase-Stat signaling PMID: 26896692
  32. HCV infection is proposed to induce a more efficient antiviral response in individuals with the IFNL4 TT/TT genotype that results either in viral clearance or selection for viral adaptations. PMID: 25849245
  33. IFN-l4 may have at least 3 functions in human hepatic cells-activation of interferon signaling, inhibition of cell proliferation, and induction of cell death PMID: 26134097
  34. data on ex vivo derived liver tissue samples argue against an attenuating impact of IFNL3 rs4803217 or IFNL4 rs368234815 minor alleles on hepatic IFNL3 gene expression in vivo. PMID: 26606750
  35. The described is the association with spontaneous hepatitis C viral clearance and genetic differentiation of IL28B/IFNL4 haplotypes in populations from Mexico. PMID: 26741362
  36. The hepatitis C protective allele TT was associated with decreased likelihood of HIV-1 infection in male intravenous drug users [odds ratio (OR): 0.3; P = 0.006], and this association was not modified by the genotype of CCR5. PMID: 26372394
  37. IFNL3 and IFNL4 genotyping could identify those likely to clear naturally and in whom treatment could be delayed, or help prioritize Directly-acting antivirals treatment to those less likely to respond to interferon-containing regimens. PMID: 26150150
  38. IFNL4-DeltaG/TT genotype was not associated with HSV-related outcomes, including episodes of oral or genital herpes PMID: 26431156
  39. Transcriptome analysis reveals a classical interferon signature induced by IFNlambda4 in human primary cells PMID: 26066369
  40. The current study is the first to investigate the effect of IFNL3 and IFNL4 polymorphisms on liver-related mortality. The lower risk of death among African American HIV/HCV-coinfected women is not explained by genetic variation in the IFN-lambda region. PMID: 26115445
  41. Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Chronic Hepatitis B. PMID: 26225703
  42. Single-nucleotide polymorphisms (SNPs) in the interferon lambda 4 (IFNL4) gene are predictors for treatment success in patients with hepatitis C virus (HCV) infection PMID: 26406534
  43. Natural selection history of IFNL4-inactivating allele has thus shaped present-day heterogeneity across populations not only in genetic variation, but also in relevant phenotypes and susceptibility to hepatitis C. PMID: 25329461
  44. The IFNL3.rs12979860 and IFNL4.ss469415590 variants have comparable effects on spontaneous resolution of hepatitis C virus infection among Egyptians. PMID: 25788203
  45. Interferon-lambda rs12979860 genotype is a strong aetiology-independent predictor of tissue inflammation and fibrosis in viral and non-viral chronic liver disease. PMID: 25740255
  46. IFNL4 polymorphisms were predictive of treatment outcome only for patients infected with HCV-1. PMID: 25938236
  47. Females with the IFNL4 genotype detected were more likely to have HCV reclearance. PMID: 25883387
  48. We found an independent association of the IFNL4 ss469415590 polymorphism with higher prevalence of AIDS-defining illnesses and lower CD4 T cell numbers. PMID: 25658540
  49. Overexpression of IFNlambda4 suppressed IL28B induction and promoter activation. PMID: 25611696
  50. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients PMID: 25675103
  51. Patients harbouring the impaired IFNlambda4-S70 variant display lower interferon-stimulated gene (ISG) expression levels. PMID: 25534433
  52. Studies indicate that the type III interferons (IFNs) or IFN-lambdas consists of four members: IFN-lambda1 (IL-29), IFN-lambda2 (IL28A), IFN-lambda3 (IL-28B) and IFN-lambda4. PMID: 26194286
  53. this review summarizes the current knowledge of IFN-l4 and discusses questions that should be addressed to resolve its paradoxical biologic activities.[review] PMID: 24786669
  54. IFNL4 gene polymorphisms can predict treatment response in chronic hepatitis C. PMID: 25393304
  55. Authors report for the first time an association between an IFNL3/4 polymorphism and susceptibility to AIDS-related cytomegalovirus retinitis. PMID: 25259701
  56. This study demonstrates that IFNL4 rs368234815 polymorphism is an important predictor of response to antiviral treatment in the liver transplantation setting. PMID: 25130512
  57. Polymorphisms in the IFNL3/4 region influence susceptibility to cytomegalovirus replication in solid-organ transplant recipients. PMID: 25301956
  58. Genetic analysis revealed associations of rs368234815 of IFNL4 with sustained virological response and pre-treatment viral load. PMID: 25577150
  59. IFNL3 and IFNL4 single nucleotide polymorphisms correlate with treatment response in hepatitis C patients depending on virus genotype. PMID: 24782280
  60. HCV infection in particular might activate IFNL4 transcription in the liver PMID: 24376784
  61. Among Puerto Rican hepatitis C patients, SNP frequencies of IFNL4 locus ss469415590 were 26% (TT/TT), 48% (TT/DeltaG), and 26% (DeltaG/DeltaG). PMID: 25563035
  62. IFNL4 improves prediction of response to interferon-based hepatitis C therapies, if SNP rs8099917 is used. PMID: 24205831
  63. Its polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus. PMID: 24325405
  64. genetic polymorphism is associated with antiviral therapy outcome in the Japanese population PMID: 24355007
  65. could not find any difference in the predictive impact of any of three SNPs of IFNL4 or IL-28B with regard to susceptibility to HCV or treatment response PMID: 24646752
  66. Intrahepatic lymphocyte degranulation activity in HCV-infected patients is associated with IFNL4 polymorphisms and contributes to the clearance of HCV in patients with favorable genotypes under antiviral therapy. PMID: 24415789
  67. It was reported that in patients treated with sofosbuvir along with ribavirin, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus and decreased drug efficacy. PMID: 24367041
  68. IFNL4-DeltaG is strongly associated with impaired spontaneous hepatitis C virus clearance. PMID: 23956438
  69. A new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. PMID: 23291588

Show More

Hide All

Subcellular Location Cytoplasm, Secreted
Protein Families Lambda interferon family
Database Links

HGNC: 44480

OMIM: 615090

KEGG: hsa:101180976

UniGene: Hs.745579

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1